Hengrui Pharma(SH:600276) Ge Long Hui·2025-09-25 02:35Core Viewpoint - Heng Rui Medicine (600276.SH) has received the acceptance notice from the National Medical Products Administration for its drug SHR7280, marking a significant step towards market approval for this oral GnRH receptor antagonist [1] Company Summary - The drug SHR7280 is an oral small molecule GnRH receptor antagonist designed to block the binding of endogenous GnRH to its receptor, thereby inhibiting the synthesis and release of luteinizing hormone (LH) and other gonadotropins [1] - SHR7280 is intended for use in controlled ovarian hyperstimulation treatments within assisted reproductive technology [1] Industry Summary - There are currently no approved oral GnRH antagonists in the domestic and international assisted reproductive fields, indicating a potential market opportunity for SHR7280 [1]